Anvisa refused Sputnik V because the version presented to Anvisa differs from the one presented in Lancet: https://brazilian.report/liveb...
Anvisa has a strong scientific background and reliable history to be not influenced by political pressure.
Here in Brazil, after our FDA equivalent approved the studies about CoronaVac at the beginning of 2021, and due this, it was the first vaccine we started to produce in mass against the Corona virus. My father has more than 70, a hearth disease and diabetes. One month after the second shot, he got the virus. He felt some body pain for 2 days, and during 3 days, a bit of difficulty to breath. But he recovered well and was not even required to go to the hospital. More important: he is alive! Same with my uncle, older than him. My stepmother, around 55 has not the same luck: she still didn't receive the vaccine and gone to the hospital for 3 weeks, received oxygen, and now she is back to home, alive, thankfully, with some minor sequels.
So, of course, if I could choose, I would pick Pfizer or any one with higher efficiency for my father. But even "ok" vaccines like CoronaVac are better than no vaccine in poor countries like here.
"More software projects have gone awry for lack of calendar time than for all other causes combined." -- Fred Brooks, Jr., _The Mythical Man Month_